BidaskClub upgraded shares of Reata Pharmaceuticals (NASDAQ:RETA) from a hold rating to a buy rating in a report issued on Wednesday morning.
Several other equities analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Reata Pharmaceuticals from a hold rating to a sell rating in a research report on Thursday, May 3rd. ValuEngine upgraded shares of Reata Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, May 2nd. Finally, Cowen restated a hold rating on shares of Reata Pharmaceuticals in a research report on Monday, April 9th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of Buy and a consensus target price of $54.71.
NASDAQ RETA traded up $1.75 on Wednesday, hitting $31.76. The company’s stock had a trading volume of 279,320 shares, compared to its average volume of 223,690. The company has a debt-to-equity ratio of -0.12, a quick ratio of 2.80 and a current ratio of 2.62. Reata Pharmaceuticals has a 1-year low of $30.07 and a 1-year high of $31.90. The stock has a market cap of $755.85 million, a P/E ratio of -15.96 and a beta of 0.10.
Reata Pharmaceuticals (NASDAQ:RETA) last announced its quarterly earnings results on Tuesday, May 8th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.61) by $0.76. The business had revenue of $32.39 million during the quarter, compared to analyst estimates of $10.21 million. analysts predict that Reata Pharmaceuticals will post -2.47 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Citadel Advisors LLC acquired a new stake in shares of Reata Pharmaceuticals during the first quarter worth $497,000. Landscape Capital Management L.L.C. increased its position in shares of Reata Pharmaceuticals by 229.9% during the first quarter. Landscape Capital Management L.L.C. now owns 53,639 shares of the company’s stock worth $1,100,000 after buying an additional 37,381 shares during the period. Stifel Financial Corp increased its position in shares of Reata Pharmaceuticals by 247.7% during the first quarter. Stifel Financial Corp now owns 28,170 shares of the company’s stock worth $575,000 after buying an additional 20,069 shares during the period. Northern Trust Corp increased its position in shares of Reata Pharmaceuticals by 1.4% during the first quarter. Northern Trust Corp now owns 129,984 shares of the company’s stock worth $2,666,000 after buying an additional 1,735 shares during the period. Finally, King Luther Capital Management Corp increased its position in shares of Reata Pharmaceuticals by 10.1% during the first quarter. King Luther Capital Management Corp now owns 63,495 shares of the company’s stock worth $1,302,000 after buying an additional 5,837 shares during the period. Institutional investors own 49.24% of the company’s stock.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease.
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.